Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Specific anti hepatocellular carcinoma dendritic cells implantation
DRKS00016606Phase 2Completed
- Sponsor
- Tanta University
- Start
- Jan 2019
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of TriMix-DC in hepatocellular carcinoma (HCC) (4 arms), sponsored by Tanta University. Started Jan 2019; status: completed.
02
Drugs
TriMix-DC
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on DRKS00016606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00016606.